NCT06402487View on ClinicalTrials.gov

Propionic Acid in Multiple Sclerosis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

September 15, 2024

Study Completion Date

October 9, 2024

Conditions
Multiple Sclerosis
Interventions
DIETARY_SUPPLEMENT

Propionic acid 1000 mg capsule

Patients will be assigned to propionic acid or placebo as add on MS treatment.

DIETARY_SUPPLEMENT

Placebo

Patients will be assigned to propionic acid or placebo as add on MS treatment.

Trial Locations (1)

5020

Salzburger Landeskliniken, Salzburg

All Listed Sponsors
lead

Salzburger Landeskliniken

OTHER

NCT06402487 - Propionic Acid in Multiple Sclerosis | Biotech Hunter | Biotech Hunter